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Abstract
TP53, a tumor suppressor gene, has a critical role in cell cycle,
apoptosis and cell senescence and participates in many crucial physi-
ological and pathological processes. Identification of TP53 polymor-
phism in older people and age-related diseases may provide an under-
standing of its physiology and pathophysiological role as well as risk
factors for complex diseases. TP53 codon 72 (TP53:72) polymor-
phism was investigated in 383 individuals aged 66 to 97 years in a
cohort from a Brazilian Elderly Longitudinal Study. We investigated
allele frequency, genotype distribution and allele association with
morbidities such as cardiovascular disease, type II diabetes, obesity,
neoplasia, low cognitive level (dementia), and depression. We also
determined the association of this polymorphism with serum lipid
fractions and urea, creatinine, albumin, fasting glucose, and glycated
hemoglobin levels. DNA was isolated from blood cells, amplified by
PCR using sense 5'-TTGCCGTCCCAAGCAATGGATGA-3' and
antisense 5'-TCTGGGAAGGGACAGAAGATGAC-3' primers and
digested with the BstUI enzyme. This polymorphism is within exon 4
at nucleotide residue 347. Descriptive statistics, logistic regression
analysis and Student t-test using the multiple comparison test were
used. Allele frequencies, R (Arg) = 0.69 and P (Pro) = 0.31, were
similar to other populations. Genotype distributions were within
Hardy-Weinberg equilibrium. This polymorphism did not show sig-
nificant association with any age-related disease or serum variables.
However, R allele carriers showed lower HDL levels and a higher
frequency of cardiovascular disease than P allele subjects. These
findings may help to elucidate the physiopathological role of TP53:72
polymorphism in Brazilian elderly people.
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Introduction
TP53, a tumor suppressor gene, has a
critical role in cell cycle, apoptosis and cell
senescence and participates in many crucial
physiological and pathological processes (1).
Also, TP53 is central in protecting against
neoplastic diseases in humans and may af-
fect survival (2).
TP53 plays an important role in regulat-
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ing vascular smooth muscle cell growth and
may mediate an abnormal occurrence of ap-
optosis in atherosclerotic lesions by attenu-
ating or accelerating the apoptotic death pro-
cess (3). This protein has been observed in
unstable atherosclerotic carotid plaque and
the p53 pathway may be activated by lipid
peroxidation products, as observed in hu-
man neuroblastoma cells (4). Furthermore,
the involvement of p53 in some age-associ-
ated morbidities such as diabetes (5) and
fatty liver diseases (6) has also been de-
scribed.
Functional analysis of TP53 codon 72
(TP53:72) variants showed differences in
their transactivating activity, transforming
capacity and apoptosis induction as well as
in binding a variety of proteins. TP53 variant
protein R72 (Arg) is significantly more effi-
cient than P72 (Pro) in inducing apoptosis
while P72 appears to induce a higher level of
G1 arrest (1,7).
A remarkable activity of p53 has been
described in mutant mice which display early
aging-associated phenotypes (8,9). Among
continental Italian and Sardinian centenar-
ians, these variants did not have a sufficient
impact on age-related mortality so as to alter
gene frequency with age (2). On the other
hand, a prospective study of 1226 people
aged 85 years and over showed a 41% sur-
vival rate for Pro/Pro genotype carriers (10).
An association between RR genotype and
minimum lumen diameter 3 months after
angioplasty has been reported in Japanese
patients (11). Zee et al. (12) demonstrated
that TP53 haplotypes, including R72P poly-
morphism, have protective effects on reste-
nosis after angioplasty mainly due to the P72
allele. Bonafe et al. (13) observed a higher
extension of oxidative stress-induced apop-
tosis in isolated fibroblast and lymphocyte
cells from Italian centenarians and sexage-
narians with the RR genotype. The RR geno-
type modulates in vivo ischemia-induced cell
death in patients with acute coronary syn-
drome (13) and was also found to be associ-
ated with a poor outcome in patients with
traumatic brain injury (14).
Investigation of this polymorphism in
109 Alzheimer disease patients did not show
association and did not reveal an interactive
effect with apolipoprotein E allele ε4 (15).
In the present study, we determined al-
lele and genotype frequencies and the asso-
ciation of TP53:72 polymorphism with mor-
bidities such as cardiovascular disease, type
II diabetes, obesity, neoplasia, low cognitive
level (dementia), and depression, as well as
with serum lipid and protein levels, in a
cohort of elderly subjects followed in longi-
tudinal study in São Paulo, Brazil. To our
knowledge, there are no literature reports
investigating the association of TP53:72 with
all of these morbidities. Lipids, proteins,
urea, creatinine, fasting glucose, and glycated
hemoglobin were also investigated concern-
ing this polymorphism.
Material and Methods
Population
The study population consisted of 383
participants from an Elderly Longitudinal
Study (16). This study began in 1991 and
originally involved 1667 people over the
age of 66 years living in a São Paulo com-
munity, Brazil. Subjects were clinically
evaluated every two years and a subsample
of 383 in wave 4 (2000-2001) were invited
to participate in the present study. This popu-
lation was composed of individuals of Euro-
pean (89.2%), Japanese (3.3%), Middle East-
ern (1.81%), and mixed and/or other origin
(5.70%). The mean age of this population
cohort was 79.80 ± 5.32 years (range: 66-97
years).
Clinical inquiries were performed to ob-
tain information about medical history, cur-
rent medication use, lifestyle, and anthropo-
metric measurements. Physicians performed
a physical exam and blood samples were
collected for laboratory procedures. The
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Research Ethics Committee of UNIFESP
approved this study and all participants gave
written informed consent.
Subjects were considered positive for
cardiovascular disease when they self-re-
ported previous myocardial infarction and/
or coronary heart disease, cerebrovascular
disease and/or transitory ischemic attacks
and were also taking specific medication
prescribed by physicians. Those currently
taking insulin or oral medication and those
with fasting glucose equal to or above 126
mg/dL were considered positive for type II
diabetes (17). Subjects were considered to
be positive for neoplasia when they self-
reported a previous diagnosis with confir-
mation by the results of histological exams
in their medical records. Subjects with a
body mass index above 27 kg/m2 were con-
sidered to be obese (18,19). Cognitive func-
tion was evaluated by the Mini-Mental State
Examination screening instrument (20) vali-
dated for the Brazilian population (21). A
Mini-Mental State Examination score of less
than 24 (of 30) has 80-90% sensitivity and
80% specificity for discriminating subjects
with low cognition level, roughly classified
as dementia, from normal subjects (21,22).
Depression was characterized by a score
above 5 in a validated Brazilian version of
the instrument from Older Americans Re-
sources and Services (23).
Although some studies have shown that
self-reported past history and medical records
are usually concordant for selected medical
conditions in the elderly (24), past histories
were only accepted when there was also
evidence in physical examinations, ECG,
CT-scan or physician reports.
TP53:72 polymorphism was also inves-
tigated in 56 elderly healthy controls, rang-
ing in age from 56 to 95 years (mean age:
73.07 ± 8.18 years) and 59 young healthy
controls ranging in age from 7 to 23 years
(mean age: 20.3 ± 1.5 years). The elderly
control sample was composed of 89.3% Eu-
ropean, 5.4% Japanese, 1.8% Afro-Brazil-
ian, and 3.5% mixed origin subjects. The
young control sample was composed of
89.8% European, 8.5% Japanese, and 1.6%
mixed origin subjects.
Laboratory exams
Lipid and lipid fraction measurements
were performed by routine enzymatic tests.
Creatinine, albumin, urea, and fasting serum
glucose levels were investigated by usual
colorimetric, kinetic and UV tests. Glycated
hemoglobin levels were analyzed by high-
performance liquid chromatography (25).
DNA extraction
Blood was collected into tubes contain-
ing 0.1% EDTA and genomic DNA was
isolated using procedures modified from
Lahiri and Nurnberger (26).
Genotyping
TP53 R72P polymorphism was analyzed
using procedures modified from Helland et
al. (27) and Ara et al. (28). A 199-bp se-
quence containing the polymorphic site was
amplified by PCR using sense 5'-TTGCC
GTCCCAAGCAATGGATGA-3' and anti-
sense 5'-TCTGGGAAGGGACAGAAGAT
GAC-3' primers.
Each PCR mixture contained 50 ng ge-
nomic DNA and PCR buffer, MgCl2, dNTPs,
Taq polymerase, and primers. The mixture
was heated for 4 min at 95ºC and underwent
35 cycles of amplification: annealing (55ºC
for 30 s), extension (72ºC for 45 s) and
denaturation (94ºC for 45 s). The PCR prod-
uct was digested with BstUI for 4 h at 60ºC,
producing two fragments of 113 and 86 bp in
relation to the R allele and a fragment with
199 bp in relation to the P allele.
Restriction fragment length polymor-
phism products were analyzed on 4% GTG
agarose gel and stained with ethidium bro-
mide. Figure 1 shows the TP53 R72P alleles
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Figure 1. A, PCR product amplification of TP53 codon 72 gene. Lanes 1-7: PCR products; C: negative control and M (100 bp): 100-bp DNA marker
(Gibco, Gaithersberg, MD, USA). B, Restriction fragment length polymorphism on 4% GTG agarose gel. Lane 1: P (Pro) allele (199 bp); lanes 2 and 6:
R (Arg) allele (113 + 86 bp), and lanes 3, 4, 5, and 7: PR genotype (199 + 113 + 86 bp). M (25 bp): 25-bp DNA marker (Gibco).
199 bp
600 bp
199 bp
113 bp
86 bp
200 bp
100 bp
200 bp
125 bp
100 bp
25 bp
1 2 3 4 5 6 7 C M (100 bp) 1 2 3 4 5 6 7 M (25 bp)A B
and genotypes obtained from restriction frag-
ment analysis.
Statistical analysis
Descriptive statistics, logistic regression
analysis, chi-square test, and t-test were per-
formed using SPSS 10.0. Genotype and al-
lele frequencies were calculated by allele
counting as described by Emery (29). Geno-
type distribution was investigated in terms
of Hardy-Weinberg equilibrium. Two allele
groups were considered for statistical analy-
sis: one with a P allele (PP + PR genotypes
together) and the other with a non-P allele
(RR genotype). The mean age of subjects
with the P allele was 79.57 ± 5.40 years and
the mean age of subjects with the non-P
allele was 80.06 ± 5.23 years. Age compar-
ison between allele groups did not show a
significant difference (t = 0.894; d.f. = 381;
P = ns). Gender association with morbidity
was also evaluated in the entire sample using
the chi-square test (α = 0.05).
Logistic regression analysis for the in-
vestigation of polymorphism association with
morbidity was performed considering the
allele as a dependent variable and morbidity,
age and sex as co-variables in the model.
Odds ratios and 95% confidence interval
were calculated using the SPSS 10.0 soft-
ware. The Student t-test was used to com-
pare laboratory findings for P and non-P
allele carriers (α = 0.05).
Results
The allele frequencies observed in our
population were 0.31 for the P allele and
0.69 for the R allele. Observed genotype
frequencies were 0.47 for RR, 0.44 for PR,
and 0.09 for PP. Genotype distributions were
within Hardy-Weinberg equilibrium for the
whole sample, elderly and young controls
and for the groups with cardiovascular dis-
ease, type II diabetes, obesity, and neoplasia
(data not shown). Genotype distribution and
allele frequency for the whole sample and
the subsamples are shown in Table 1.
Logistic regression analysis revealed a
tendency of the R allele (non-P allele) to
associate with cardiovascular disease (Table
2). Table 3 shows descriptive statistics and
Student t-test values for the two allele groups
concerning laboratory findings. We detected
an association of the R allele with lower
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Table 1. Number and distribution of TP53:72 genotypes and alleles in a Brazilian elderly cohort and in elderly
and young healthy controls.
Genotypes Allele frequencies
PP PR RR Total P R
Whole sample 33 169 181 383 0.3068 0.6932
Male 15 55 51 121 0.3512 0.6488
Female 18 114 130 262 0.2863 0.7137
Elderly controls 3 21 32 56 0.2411 0.7589
Young controls 3 31 35 59 0.2681 0.7319
Affected subjects Total P R
Cardiovascular 5 32 46 83 382 0.2530 0.7470
Type II diabetes 26 102 114 242 382 0.3182 0.6818
Obesity 12 55 60 127 308 0.3110 0.6890
Depression 4 40 27 71 354 0.3380 0.6620
Low cognitive level 0 17 13 30 376 0.2833 0.7167
Neoplasia 2 20 19 41 378 0.2927 0.7073
Table 3. Descriptive statistics concerning P allele and non-P allele carriers and laboratory findings.
P allele carriers Non-P allele carriers
N Mean ± SD N Mean ± SD
Triglycerides 135 147.53 ± 77.75 112 151.89 ± 62.96
Cholesterol 135 216.74 ± 41.45 112 214.88 ± 44.20
HDL 135 55.96 ± 15.27 111 52.41 ± 12.57
LDL 130 131.06 ± 33.88 109 132.78 ± 38.39
VLDL 131 27.62 ± 11.45 110 29.73 ± 11.00
Creatinine 130 0.9669 ± 0.2501 108 0.9324 ± 0.2254
Urea 131 40.95 ± 13.31 108 39.81 ± 11.72
Albumin 130 4.0669 ± 0.3099 108 4.0019 ± 0.3399
Fasting glucose 180 98.07 ± 35.32 168 100.10 ± 28.61
Glycated hemoglobin 105 4.8857 ± 1.3273 114 5.0342 ± 1.3917
Table 2. Logistic regression results concerning association between morbidities and TP53:72 polymorphism
in a cohort from a Brazilian elderly population.
Variables P value Odds ratio 95% confidence interval
P allele/non-P allele Lower Upper
Cardiovascular disease 0.071 0.638 0.389 1.045
Type II diabetes 0.865 1.000 0.629 1.476
Obesity 0.662 0.901 0.565 1.438
Depression 0.075 1.634 0.953 2.801
Low cognitive level 0.599 1.226 0.574 2.615
Neoplasia 0.952 1.020 0.531 1.962
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HDL levels (P = 0.047). Serum triglyceride,
total cholesterol, VLDL, LDL, urea, creati-
nine, albumin, fasting glucose, and glycated
hemoglobin levels did not show significant
differences between P allele carriers and
non-P allele carriers (Student t-test).
Discussion
Studies conducted on older populations
have the advantage of demonstrating specif-
ic aspects of the aging process. Our sample
was mostly composed of European descen-
dents and our results concerning allele and
genotype frequencies are similar to those
reported in other studies on populations of
the same ethnic composition. Another study
on a Brazilian adult population reported the
following genotype frequencies: RR = 0.518,
PR = 0.405, and PP = 0.078 (30). A study on
a Chilean adult population sample reported
similar frequencies: RR = 0.472, PR = 0.453,
and PP = 0.075 (31), as also reported for a
Mexican sample (RR = 0.45, PR = 0.62, and
PP = 0.08) (32).
Female gender was associated with obe-
sity in our sample (P = 0.011), confirming
the findings of a Brazilian epidemiological
study involving residents over 60 years in
the Bambuí community, Minas Gerais State
(33). Another epidemiological investigation
in the Northeast and Southeast regions of
Brazil also showed higher a prevalence of
obesity among women older than 50 years
(34).
Genotype distribution was within Hardy-
Weinberg equilibrium in the whole sample
and in all the subsamples, except for the
depression and low cognitive level groups.
TP53 variants did not have a sufficient im-
pact on age-related mortality so as to alter
gene frequency in comparison with the young
control group (P = 0.081) in this sample.
TP53:72 polymorphism did not show a
significant association with any age-related
morbidity or serum variable. Our population
is mainly composed of European descen-
dants, especially from Portugal, Spain, and
Italy. In Spanish and Italian populations, the
R allele has been associated with restenosis
after angioplasty and with a greater extent of
cells with oxidative stress in centenarians
and sexagenarians (2,12). This ethnic com-
position may account for the observed ten-
dency of the R allele to associate with car-
diovascular disease and lower HDL levels.
The relationship between TP53 and lipid
metabolism is not well known but many
reports support correlations. Lower levels of
HDL lipoprotein have been considered to be
an independent risk factor for cardiovascu-
lar disease and type II diabetes (35). More-
over, modification of low-density lipopro-
tein by endothelial cells has been associated
with lipid peroxidation and with degradation
of low-density lipoprotein phospholipids (36).
In addition, the lipid peroxidation product
has also been considered a potential trigger
of the p53 pathway in human neuroblastoma
cells. Patients with acute myocardial infarc-
tion showed four times higher levels of se-
rum oxidized LDL compared to control (37).
Our findings also did not show an asso-
ciation of the polymorphism with type II
diabetes or with some serum variables asso-
ciated with impaired renal function, although
the p53 pathway contributes to an altered
neovascularization process in diabetes (38).
These findings may help to elucidate the
physiopathological role of TP53:72 poly-
morphism in elderly Brazilian people.
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